[{"data":1,"prerenderedAt":279},["ShallowReactive",2],{"story-209091-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":48,"questions":49,"relatedArticles":74,"body_color":277,"card_color":278},"209091",null,"Generic Drug Tariffs 100% by 2028 | Cross-Border Sellers Face Supply Crisis","- Effective August 2028, imported generics face 100% duty escalating to 200% by 2029; India/China sourcing becomes unviable; small-to-mid sellers lose 40-60% margins on pharmaceutical products",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,21,23,24,25,26,27,28,29,30,31,17,18,32,33,34,35,36,37,38,39,40,19,41,42,43,22,44,33,45,46,47],"https://www.dcatvci.org/wp-content/uploads/2025/02/iStock-1001502582-1.jpg","https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-645x645.jpg","https://image.cnbcfm.com/api/v1/image/108339030-17847904971784790493-47335310376-1080pnbcnews.jpg?v=1784790496&w=750&h=422&vtcrop=y","https://imageio.forbes.com/specials-images/imageserve/6a60daaff73e4d8265aad21e/Variety-Of-Pills-And-Capsules--Close-Up-/1960x0.jpg?height=473&width=711&fit=bounds","https://static.time.com/v3/assets/bltea6093859af6183b/blt50b7a93ab56492f0/6a62639d85ffee2dd527c62e/Generic-Drugs-Tariffs.jpg?branch=production&width=3840&quality=75&auto=webp&crop=3:2","https://image.cnbcfm.com/api/v1/image/108336351-1784251467141-gettyimages-2285785852-AFP_C2EX37T.jpeg?v=1784251495&w=1600&h=900","https://static.toiimg.com/thumb/msid-132569828,width-1280,height-720,imgsize-142462,resizemode-4,overlay-toi_sw,pt-32,y_pad-600/photo.jpg","https://www.thedailyupside.com/wp-content/uploads/2026/07/sipaphotostwentyseven302363-scaled-e1784747100924.jpg","https://www.washingtonexaminer.com/wp-content/uploads/2025/12/iStock-1202498704-e1784730318924.jpg?resize=1200,683","https://imgproxy.divecdn.com/nPow6DTNGLvXiFogeQ3sE2l5JX3D825iebn7hUK0MyU/g:nowe:0:0/c:3200:1807/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjg3MTgyNTQxLmpwZw==.webp","https://www.reuters.com/resizer/v2/G2BIKLLJRRKY5JPCQI63HTFJP4.jpg?auth=c6d554ac3f68d346fa23813b1ff67b1cbd40a92f96675edec338f79a473f6769&width=1920&quality=80","https://imgproxy.divecdn.com/byxOD3GwWuBHXrMYAYKAG78Qufhw3izUBK9blhky4No/g:nowe:0:0/c:3200:1807/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjgxMTE5MDMyLmpwZw==.webp","https://www.reuters.com/resizer/v2/JTZILSYETBONLGHQ5Q64GURKGI.jpg?auth=f7a35164f246bd5265b2af2a5678f8c5161a8262bb50e1867437b136b85950b6&width=1920&quality=80","https://www.businessreport.com/wp-content/uploads/2026/06/Business-Report-2026-default-image.jpg","https://assets.realclear.com/images/64/646887_4_.jpeg","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iggATuYA33mk/v3/620x-1.jpg","https://prosperousamerica.org/wp-content/uploads/2026/07/medicine-cabinet-featured.jpg","https://images.wsj.net/im-360236?width=700&height=466","https://cdn.i-scmp.com/sites/default/files/styles/700x400/public/d8/images/canvas/2026/07/22/96667156-e9ce-427b-9571-2c23ce482933_8c988789.jpg?itok=cFaU2nHw&v=1784712882","https://i0.wp.com/asiatimes.com/wp-content/uploads/2026/07/2027986-untitled-design-2026-04-03t225843740-copy.jpg?fit=780%2C468&ssl=1","https://s.yimg.com/lo/mysterio/api/A0CDE8DA6A90BD6ED313CADF4933384CD6B346D396C6C5253742EBF88CACC9B6/subgraphmysterio/resizefit_w960;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fproactive_us_504%2Fea6097a6dd5fc42a25880a7a5760cd94","https://th-i.thgim.com/public/incoming/26fsek/article71254968.ece/alternates/LANDSCAPE_1200/2026-07-22T151217Z_943419862_RC2XIMABQMJ6_RTRMADP_3_IRAN-CRISIS-TRANSFER-USA.JPG","https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/07/shutterstock_2757926535-430x241.jpg","https://assets.newsweek.com/wp-content/uploads/2026/07/GettyImages-1458838272-Custom.jpg","https://www.politico.eu/cdn-cgi/image/width=1160,height=773,quality=80,onerror=redirect,format=auto/wp-content/uploads/2026/07/22/GettyImages-2248128894-scaled.jpg","https://s.yimg.com/lo/mysterio/api/DCEBFB9D124710093000442BCFCF33B3A9389C2824482FF875B6FFC9004254B9/subgraphmysterio/resizefit_w960_h540;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fwfrv_articles_965%2Fb358993f5d7337faae6dd3dc29b27adb","https://thehill.com/wp-content/uploads/sites/2/2026/07/6a465e97c4ede0.46237411.jpeg?strip=1","https://cdn.sanity.io/images/0vv8moc6/pharmexec/b2defa6b4904a34b5dfa8d86ebaaae1c7a81931b-1280x720.png/pharma%20finance%2016x9.png?w=1280&max-h=720&fit=crop&auto=format","https://ednews.net/en/wp-content/uploads/sites/2/2026/07/Medicines-1024x536.webp","https://storage.googleapis.com/media.mwcradio.com/mimesis/2026-07/22/2026-07-22T085136Z_1_LYNXMPEM6L0ON_RTROPTP_3_USA-TRUMP-TARIFFS.JPG","https://s.yimg.com/lo/mysterio/api/604f3fa622713b9b6b519fcee36a5a84de8932d922d49968d59e973fca4faa1b/lightyear_networkapi/resizefill_w960;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fmeidastouch_articles_379%2F39413ffd202eafcc3ff4c3822d199361","https://static.toiimg.com/thumb/msid-132562787,width-1280,height-720,imgsize-993014,resizemode-4,overlay-toi_sw,pt-32,y_pad-600/photo.jpg","https://bakersfieldnow.com/resources/media2/16x9/7518/800/0x392/80/eedfdd13-bb82-4af2-92db-4dd971986525-GettyImages2286076267.jpg","https://images.ft.com/v3/image/raw/https%3A%2F%2Fcms-image-bucket-productionv3-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F2%2F6%2F1%2F3%2F12873162-1-eng-GB%2F5b639c4445f5-2025-04-14T080408Z_607677814_RC26WDAXU750_RTRMADP_3_INDIA-PHARMA.JPG?fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&width=780","https://ca-times.brightspotcdn.com/dims4/default/d50d5cd/2147483647/strip/true/crop/2000x1333+0+0/resize/1200x800!/quality/75/?url=https%3A%2F%2Fcalifornia-times-brightspot.s3.amazonaws.com%2F78%2Ff8%2Fe4999cbbe42dafd550c635ba21b7%2F1x-1.jpg","https://assets3.cbsnewsstatic.com/hub/i/r/2026/07/22/accdc016-425c-41ab-ad52-b2fb05e25a96/thumbnail/1200x630/2b0e0f907067b0639b119bf5e0e819f2/gettyimages-1220583234.jpg","https://s.yimg.com/lo/mysterio/api/08622EDB3D9A72AE92B975A2060BE3A7DEE83BFF7962B015402A8E9A7FA6DEDE/subgraphmysterio/resizefill_w1200_h675;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fus.finance.thefiscaltimes%2F170324a824387d891ee6cd5c5e33e986","**Trump administration's phased tariff policy on imported generic drugs represents a seismic shift in pharmaceutical trade policy with direct implications for cross-border e-commerce sellers.** Announced July 21, 2026, the policy imposes a 100% tariff on generic drug imports effective August 2028, escalating to 200% by August 2029. This creates an immediate 24-month window for sellers to restructure supply chains before tariffs effectively double product costs. Generic drugs represent 90% of US prescriptions but only 20% of pharmaceutical spending, making them critical for price-sensitive consumer segments. India supplies approximately 50% of US generic medicines while China supplies 80% of active pharmaceutical ingredients, meaning sellers sourcing from these regions face complete supply chain disruption.\n\n**For cross-border e-commerce sellers, the tariff structure creates three distinct operational scenarios.** Small and mid-sized sellers (annual pharmaceutical sales $100K-$5M) currently sourcing from India/China face margin compression of 40-60% if they absorb tariff costs, or forced price increases of 50-100% if passed to consumers. The 100% duty effectively doubles landed costs—a $4 generic medication becomes $8 at import, making it economically unviable against brand-name alternatives ($157 per unit). Large sellers with $5M+ annual pharmaceutical revenue can negotiate domestic manufacturing partnerships or establish 3PL relationships with US-based producers, but require 12-18 months and $500K-$2M capital investment to execute. The two-year implementation window (August 2026 to August 2028) provides planning time but insufficient runway for most sellers to establish domestic sourcing without significant operational disruption.\n\n**Strategic sourcing alternatives emerge as the primary competitive advantage.** Sellers who establish relationships with US-based generic manufacturers or contract manufacturers in tariff-exempt countries (Mexico under USMCA, certain Caribbean nations under CBI) can maintain margin structures. India's pharmaceutical stocks fell 1.3% immediately following the announcement, signaling market recognition that Indian exporters will lose US market share. Domestic US generic manufacturers like Sandoz, Teva, and Mylan face increased demand but also capacity constraints—existing US production capacity cannot absorb 90% of current import volumes within 24 months. This creates a temporary supply shortage window (2028-2030) where sellers with pre-established domestic relationships gain competitive advantage. Sellers without domestic sourcing alternatives face three choices: exit the pharmaceutical category entirely, absorb 40-60% margin compression, or raise consumer prices 50-100% and accept demand destruction.\n\n**Compliance complexity and policy uncertainty create additional risk factors.** The Association for Accessible Medicines and patient advocacy groups are actively lobbying for policy modifications, suggesting the tariff structure may change before August 2028 implementation. Previous Trump tariff policies raised prices for core goods by 3.1% (Federal Reserve data through February 2025), but pharmaceutical tariffs could exceed this due to supply concentration. Sellers must monitor legislative developments quarterly and maintain flexibility in sourcing commitments. The policy's actual impact depends on implementation details—potential exemptions for critical medicines, small-business carve-outs, or phased implementation could alter the timeline. However, the 24-month window is insufficient for most sellers to wait for policy clarification; immediate action on domestic sourcing exploration is required.",[50,53,56,59,62,65,68,71],{"title":51,"answer":52,"author":5,"avatar":5,"time":5},"How should I adjust my inventory and sourcing strategy before August 2028?","Immediately conduct a sourcing audit to identify which generic medications you source from India and China (the primary tariff-affected regions). For high-volume SKUs (top 20% of sales), begin exploring domestic US sourcing alternatives and USMCA-compliant Mexican suppliers by Q4 2026. For lower-volume SKUs, consider discontinuing if domestic sourcing costs exceed brand-name alternatives. Build inventory of tariff-exempt products and establish relationships with 3PL providers who have domestic pharmaceutical distribution networks. Monitor the Federal Register monthly for tariff policy updates and legislative exemptions. By Q2 2027, you should have finalized sourcing decisions for 80% of your pharmaceutical SKUs. Avoid building excess inventory of tariff-affected products after Q2 2027, as you'll face margin compression when tariffs take effect in August 2028. Consider shifting marketing focus to higher-margin product categories (vitamins, supplements, wellness products) that face lower tariff exposure.",{"title":54,"answer":55,"author":5,"avatar":5,"time":5},"What are the competitive advantages for large sellers versus small sellers under this tariff policy?","Large sellers with $5M+ annual pharmaceutical revenue can negotiate directly with US manufacturers, establish contract manufacturing agreements, and absorb the $500K-$2M capital investment required for domestic sourcing. They can also negotiate volume discounts that offset tariff impacts. Small sellers (under $2M annual revenue) lack negotiating power with manufacturers and cannot absorb capital investment costs. They face three choices: exit the category, raise prices and accept demand destruction, or absorb margin compression. Mid-sized sellers ($2M-$5M revenue) can explore 3PL partnerships with US-based pharmaceutical distributors, but face higher per-unit costs than large sellers. The tariff policy effectively consolidates market share toward large sellers and domestic manufacturers, disadvantaging small cross-border sellers who currently rely on India/China sourcing.",{"title":57,"answer":58,"author":5,"avatar":5,"time":5},"Will the tariff policy create opportunities for sellers to gain market share in specific pharmaceutical categories?","Yes, sellers who establish domestic sourcing relationships before August 2028 can gain significant market share from competitors who exit or raise prices. High-demand generic categories (diabetes medications, hypertension drugs, antibiotics) will see supply constraints through 2030 as domestic capacity ramps up. Sellers with pre-established relationships with US manufacturers can maintain competitive pricing while competitors lose customers to price increases. Specialty generics (complex formulations, rare disease treatments) may see less tariff impact due to lower import volumes and higher margins. Sellers should focus on establishing exclusive or preferred supplier relationships with US manufacturers for high-demand categories by Q2 2027. However, this opportunity window closes after August 2028 when tariffs take effect—sellers who haven't secured domestic sourcing by then will face permanent competitive disadvantage.",{"title":60,"answer":61,"author":5,"avatar":5,"time":5},"How will the 100% generic drug tariff affect my e-commerce pharmacy business starting August 2028?","The 100% tariff will double your landed costs on imported generics from India and China, the primary sources for 50% and 80% of US generic supply respectively. A $4 generic medication will cost $8 at import, making it uncompetitive against brand-name drugs at $157. Small sellers (under $5M annual revenue) will face 40-60% margin compression unless they raise consumer prices 50-100%, which typically destroys 30-40% of demand volume. You have 24 months (August 2026 to August 2028) to establish domestic sourcing relationships or exit the category. Large sellers with $5M+ revenue can negotiate with US manufacturers like Sandoz or Teva, but require $500K-$2M capital investment and 12-18 months to execute.",{"title":63,"answer":64,"author":5,"avatar":5,"time":5},"Should I invest in domestic US generic manufacturing partnerships before August 2028?","Yes, but only if you have $500K-$2M capital available and annual pharmaceutical revenue exceeding $2M. Establishing a manufacturing partnership or contract manufacturing agreement requires 12-18 months of negotiation, regulatory approval, and production ramp-up. US generic manufacturers like Sandoz, Teva, and Mylan are capacity-constrained and prioritizing large-volume customers. Small sellers should instead explore 3PL partnerships with US-based pharmaceutical distributors who already have domestic sourcing relationships. The Association for Accessible Medicines is actively lobbying for policy modifications, so monitor legislative developments quarterly before committing capital. If you have less than $2M annual pharmaceutical revenue, consider exiting the category or shifting to brand-name products with higher margins.",{"title":66,"answer":67,"author":5,"avatar":5,"time":5},"Which countries can I source generic drugs from to avoid the 100% tariff after 2028?","Mexico offers the most viable alternative under USMCA, which provides duty-free access for qualifying pharmaceutical products. Caribbean nations under the Caribbean Basin Initiative (CBI) also offer tariff exemptions for certain generic medications. However, Mexico's generic manufacturing capacity is limited—it currently supplies only 5-8% of US generics compared to India's 50%. Establishing Mexican sourcing requires 6-12 months of supplier qualification and regulatory compliance. US domestic sourcing is the only guaranteed long-term solution, but domestic capacity cannot absorb the 90% of current import volumes within 24 months, creating a supply shortage window through 2030. Consider diversifying across Mexico, CBI countries, and domestic suppliers rather than relying on a single alternative.",{"title":69,"answer":70,"author":5,"avatar":5,"time":5},"How will the tariff affect consumer prices for generic medications on e-commerce platforms?","Generic drug prices will increase 50-100% if sellers pass tariff costs to consumers, or margins will compress 40-60% if sellers absorb costs. Federal Reserve research shows previous Trump tariffs raised prices for core goods by 3.1%, but pharmaceutical tariffs could exceed this due to supply concentration. Nearly 50% of American adults already report difficulty affording healthcare costs, and 40% skip prescribed medications due to expense. Price increases of 50-100% will likely reduce demand volume by 30-40%, particularly among price-sensitive consumer segments. This creates a demand destruction scenario where sellers lose both margin and volume. Platforms like Amazon Pharmacy and Walmart Health may shift to domestic sourcing to maintain competitive pricing, disadvantaging sellers without domestic relationships.",{"title":72,"answer":73,"author":5,"avatar":5,"time":5},"What is the timeline for the generic drug tariff implementation and are there exemptions?","The tariff begins August 1, 2026 at 0%, escalates to 100% in August 2028, and reaches 200% in August 2029. This creates a 24-month grace period for supply chain adjustment. However, the policy may be modified before implementation—patient advocacy groups and the generic drug industry are actively seeking legislative exemptions for critical medicines and small-business carve-outs. Previous Trump tariff policies included exemptions for certain categories, so monitor the Federal Register and trade policy announcements monthly. The policy's actual impact depends on implementation details that won't be finalized until 2027-2028. Don't wait for policy clarification—begin exploring domestic sourcing alternatives immediately, as the 24-month window is insufficient for most sellers to execute major supply chain changes.",[75,80,84,88,92,97,101,105,109,113,117,121,125,129,133,137,141,145,148,153,157,161,165,169,173,177,181,185,189,193,197,200,204,208,212,215,219,222,226,230,234,237,241,244,248,251,255,259,263,266,269,273],{"id":76,"title":77,"source":78,"logo":21,"time":79},1288553,"Trump threatens tariffs on imported generic drugs","https://www.biopharmadive.com/news/trump-tariffs-generic-drugs-pharmaceuticals-impact/825879/","5D AGO",{"id":81,"title":82,"source":83,"logo":13,"time":79},1288552,"The Potential Havoc Of Generic Drug Tariffs","https://www.forbes.com/sites/innovationrx/2026/07/22/the-potential-havoc-of-generic-drug-tariffs/",{"id":85,"title":86,"source":87,"logo":36,"time":79},1288556,"Trump threatens 100% generic drug tariffs beginning in 2028","https://finance.yahoo.com/economy/policy/articles/trump-threatens-100-generic-drug-152110997.html",{"id":89,"title":90,"source":91,"logo":19,"time":79},1288555,"Trump maps out 200% tariffs for generic pharmaceuticals","https://www.supplychaindive.com/news/trump-maps-out-200-tariffs-for-generic-pharmaceuticals/825882/",{"id":93,"title":94,"source":95,"logo":34,"time":96},1282813,"How Trump’s Drug Tariffs Could Hit Millions of Americans’ Medicine Bills","https://www.newsweek.com/how-trumps-drug-tariffs-could-hit-millions-of-americans-medicine-bills-12226842","4D AGO",{"id":98,"title":99,"source":100,"logo":27,"time":96},1280998,"Shares in Generic-Drug Makers Fall After Trump’s Tariff Plan","https://www.wsj.com/health/pharma/shares-in-generic-drug-makers-fall-after-trumps-tariff-plan-ed8b281c",{"id":102,"title":103,"source":104,"logo":45,"time":96},1280997,"Generic drug tariffs could send prices soaring for millions of Americans","https://www.latimes.com/business/story/2026-07-22/generic-drug-tariffs-could-send-prices-soaring-for-millions-of-americans",{"id":106,"title":107,"source":108,"logo":23,"time":96},1281008,"Roundup: Generic drug tariffs / AI eyewear / Nike’s new China play","https://www.businessreport.com/article/roundup-generic-drug-tariffs-ai-eyewear-nikes-new-china-play",{"id":110,"title":111,"source":112,"logo":42,"time":96},1282805,"Trump's 200% tariff plan may be a bitter pill for US consumers; Dr Reddy's warns of costlier medicines","https://timesofindia.indiatimes.com/business/india-business/trumps-200-tariff-plan-may-be-a-bitter-pill-for-us-consumers-dr-reddys-warns-of-costlier-medicines/articleshow/132562742.cms",{"id":114,"title":115,"source":116,"logo":15,"time":96},1280993,"Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply","https://www.cnbc.com/2026/07/22/trump-generic-drug-tariffs-prices-explained.html",{"id":118,"title":119,"source":120,"logo":28,"time":96},1281003,"What would 200% US tariffs on generic drugs mean for China’s pharmaceutical industry?","https://www.scmp.com/economy/china-economy/article/3361468/what-would-200-us-tariffs-generic-drugs-mean-chinas-pharmaceutical-industry",{"id":122,"title":123,"source":124,"logo":22,"time":96},1288550,"Generic drug sector seeks policy fixes after Trump tariff threat","https://www.reuters.com/legal/litigation/generic-drug-sector-seeks-policy-fixes-after-trump-tariff-threat-2026-07-22/",{"id":126,"title":127,"source":128,"logo":35,"time":79},1288564,"EU says Trump’s new generic drug tariffs won’t hit its exports","https://www.politico.eu/article/eu-donald-trump-new-generic-drug-tariff-export/",{"id":130,"title":131,"source":132,"logo":20,"time":79},1288563,"Generic drugmaker Sandoz to engage with US after Trump tariff threat","https://www.reuters.com/legal/litigation/generic-drugmaker-sandoz-engage-with-us-after-trump-tariff-threat-2026-07-22/",{"id":134,"title":135,"source":136,"logo":37,"time":79},1288562,"Trump threatens 100 percent generic drug tariffs beginning in 2028","https://thehill.com/policy/healthcare/5983150-trump-tariffs-generic-drugs/",{"id":138,"title":139,"source":140,"logo":26,"time":79},1288568,"The Hollowing Out of America’s Medicine Cabinet","https://prosperousamerica.org/the-hollowing-out-of-americas-medicine-cabinet/",{"id":142,"title":143,"source":144,"logo":31,"time":96},1284323,"Trump’s 200% generic tariff threat would imperil Americans: Indian pharma","https://www.thehindu.com/business/make-in-us-by-august-2028-or-pay-up-to-200-duty-trump-tells-generic-drugmakers/article71254793.ece",{"id":146,"title":90,"source":147,"logo":19,"time":96},1284325,"https://www.supplychaindive.com/news/trump-maps-out-200-tariffs-for-generic-pharmaceuticals/825882",{"id":149,"title":150,"source":151,"logo":24,"time":152},1285810,"Drug Tariffs: Onshoring or Shortages?","https://www.realclearhealth.com/2026/07/23/drug_tariffs_onshoring_or_shortages_1196154.html","3D AGO",{"id":154,"title":155,"source":156,"logo":5,"time":96},1284324,"Opinion | Trump’s generic drug tariffs will drive up pharmaceutical prices","https://www.washingtonpost.com/opinions/2026/07/22/trumps-generic-drug-tariffs-will-drive-up-pharmaceutical-prices",{"id":158,"title":159,"source":160,"logo":29,"time":96},1284327,"New Trump tariffs to block Indian, Chinese generic drugs sourcing","https://asiatimes.com/2026/07/new-trump-tariffs-to-block-indian-chinese-generic-drugs-sourcing",{"id":162,"title":163,"source":164,"logo":30,"time":152},1285812,"Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi","https://finance.yahoo.com/healthcare/articles/hikma-fresenius-best-positioned-trumps-121700256.html",{"id":166,"title":167,"source":168,"logo":44,"time":96},1284326,"Trump's generic drugs tariff threatens Indian pharma's top market","https://asia.nikkei.com/business/pharmaceuticals/trump-s-generic-drugs-tariff-threatens-indian-pharma-s-top-market",{"id":170,"title":171,"source":172,"logo":18,"time":152},1285811,"Tariff India, and half of America’s medicine cabinet could disappear","https://www.washingtonexaminer.com/op-eds/4658390/tariffs-india-american-medicine",{"id":174,"title":175,"source":176,"logo":41,"time":96},1282821,"Trump Announces Plan That Could Triple Prescription Drug Prices After Midterms","https://www.yahoo.com/news/politics/articles/trump-announces-plan-could-triple-151502774.html",{"id":178,"title":179,"source":180,"logo":11,"time":96},1284329,"Pharmalittle: We're reading about Trump's plan for tariffs on generics, a Merck and Gilead HIV pill, and more","https://www.statnews.com/pharmalot/2026/07/22/trump-plans-tariffs-on-generics-merck-gilead-hiv-pill",{"id":182,"title":183,"source":184,"logo":47,"time":96},1285814,"Trump Plans 200% Tariff on Generic Drugs","https://finance.yahoo.com/economy/policy/articles/trump-plans-200-tariff-generic-230605141.html",{"id":186,"title":187,"source":188,"logo":33,"time":96},1284328,"US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028","https://www.pharmaceutical-technology.com/news/donald-trump-us-generic-drug-tariffs",{"id":190,"title":191,"source":192,"logo":5,"time":79},1285813,"AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regula","https://www.gurufocus.com/news/8970386/astrazeneca-azn-faces-changes-amid-new-us-drug-tariff-regulations?mobile=true%3Fmobile%3Dtrue&mobile=true%3Fmobile%3Dtrue%3Fmobile%3Dtrue&mobile=true&mobile=true",{"id":194,"title":195,"source":196,"logo":43,"time":96},1285815,"Trump plans steep tariffs on imported generic drugs, raising cost and legal questions","https://bakersfieldnow.com/news/local/trump-plans-steep-tariffs-on-imported-generic-drugs-raising-cost-and-legal-questions",{"id":198,"title":77,"source":199,"logo":21,"time":96},1285809,"https://www.biopharmadive.com/news/trump-tariffs-generic-drugs-pharmaceuticals-impact/825879",{"id":201,"title":202,"source":203,"logo":5,"time":152},1285808,"Opinion | The problem with RFK Jr.’s crusade against antidepressants","https://www.washingtonpost.com/opinions/2026/07/23/rfk-jrs-crusade-against-ssri-antidepressants-needs-more-research",{"id":205,"title":206,"source":207,"logo":38,"time":96},1281013,"President Trump Announces Phased Generic Drug Tariff Plan: Report","https://www.pharmexec.com/view/president-trump-phased-drug-tariff",{"id":209,"title":210,"source":211,"logo":5,"time":79},1288576,"EU shrugs off Trump's latest tariff threat on generics","https://www.euractiv.com/news/eu-shrugs-off-trumps-latest-tariff-threat-on-generics/",{"id":213,"title":187,"source":214,"logo":33,"time":79},1288577,"https://www.pharmaceutical-technology.com/news/donald-trump-us-generic-drug-tariffs/",{"id":216,"title":217,"source":218,"logo":16,"time":96},1284776,"Pharma companies in a flux over Trump's 200% tariff move on generics","https://timesofindia.indiatimes.com/business/india-business/pharma-companies-in-a-flux-over-trumps-200-tariff-move-on-generics/articleshow/132569788.cms",{"id":220,"title":123,"source":221,"logo":22,"time":96},1284775,"https://www.reuters.com/legal/litigation/generic-drug-sector-seeks-policy-fixes-after-trump-tariff-threat-2026-07-22",{"id":223,"title":224,"source":225,"logo":10,"time":152},1288539,"A New Round in US Pharma Tariffs: What’s at Play?","https://www.dcatvci.org/features/a-new-round-in-us-pharma-tariffs-whats-at-play/",{"id":227,"title":228,"source":229,"logo":17,"time":96},1284778,"Trump’s 100% Tariffs on Generic Meds Threaten Headaches at Drugstore Checkouts","https://www.thedailyupside.com/industries/healthcare/trumps-threatened-200-tariffs-on-generic-drugs-could-spell-headaches-aat-home-and-abroad",{"id":231,"title":232,"source":233,"logo":5,"time":79},1284777,"Donald Trump reveals 200% tariff plan for generic medicines. Will India exports be hit?","https://indianexpress.com/article/world/trump-tariffs-generic-medicine-imports-india-pharma-10797664",{"id":235,"title":131,"source":236,"logo":40,"time":96},1284779,"https://wncy.com/2026/07/22/generic-drugmaker-sandoz-to-engage-with-us-after-trump-tariff-threat",{"id":238,"title":239,"source":240,"logo":25,"time":96},1279825,"Trump’s 100% Generic Drug Duty Threatens US Low-Cost Supply","https://www.bloomberg.com/news/articles/2026-07-21/trump-plans-100-tariff-on-generic-drugs-from-august-2028",{"id":242,"title":202,"source":243,"logo":5,"time":152},1288571,"https://www.washingtonpost.com/opinions/2026/07/23/rfk-jrs-crusade-against-ssri-antidepressants-needs-more-research/",{"id":245,"title":246,"source":247,"logo":14,"time":152},1288570,"Trump Plans to Impose 100% Tariffs on Generic Drugs Starting in 2028. What Would That Do to Prices?","https://time.com/article/2026/07/23/trump-generic-drug-tariff-prices-availability-impact/",{"id":249,"title":171,"source":250,"logo":18,"time":96},1288542,"https://www.washingtonexaminer.com/op-eds/4658390/tariffs-india-american-medicine/",{"id":252,"title":253,"source":254,"logo":5,"time":96},1288541,"Generic drug tariffs set to skyrocket in 2028. Consumers could feel impact","https://www.usatoday.com/story/money/2026/07/22/generic-drug-tariffs-trump-consumer-impact/91007261007/",{"id":256,"title":257,"source":258,"logo":12,"time":96},1284780,"U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO","https://www.cnbc.com/video/2026/07/23/us-pharma-tariffs-cant-be-absorbed-prices-will-rise-dr-reddys.html",{"id":260,"title":261,"source":262,"logo":32,"time":152},1288540,"3 U.S. Pharma Stocks Worth Watching After New Import Tariffs","https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/3-us-pharma-stocks-worth-watching-after-new-import-tariffs",{"id":264,"title":228,"source":265,"logo":17,"time":96},1288547,"https://www.thedailyupside.com/industries/healthcare/trumps-threatened-200-tariffs-on-generic-drugs-could-spell-headaches-aat-home-and-abroad/",{"id":267,"title":155,"source":268,"logo":5,"time":96},1288546,"https://www.washingtonpost.com/opinions/2026/07/22/trumps-generic-drug-tariffs-will-drive-up-pharmaceutical-prices/",{"id":270,"title":271,"source":272,"logo":39,"time":96},1288544,"Belgium Urges United Europe Response to Trump’s Generic Drug Tariffs","https://ednews.net/en/belgium-urges-united-europe-response-to-trumps-generic-drug-tariffs/",{"id":274,"title":275,"source":276,"logo":46,"time":96},1288548,"Trump plans 100% tariffs on imported generic drugs. Here's what experts say.","https://www.cbsnews.com/news/trump-generic-drug-tariffs-manufacturing/","#742eeeff","#742eee4d",1785184271440]